Erika Hamilton, MD
Afghahi A, Kurian AW. The changing landscape of genetic testing for inherited breast cancer predisposition. Curr Treat Options Oncol 2017;18(5):27. Abstract
Bianchini G et al. Biomarker analysis of the NeoSphere study: Pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res 2017;19(1):16. Abstract
Bonneville R et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017;2017. Abstract
Dudley JC et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016;22(4):813-20. Abstract
Litton JK et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379(8):753-763. Abstract
Robson M et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377(6):523-33. Abstract
Rugo HS et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Proc ESMO 2019;Abstract LBA20.
Schmid P et al. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Proc ESMO 2019;Abstract LBA8_PR.
Schmid P et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379(22):2108-21. Abstract
Szekely B et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol 2018;29(11):2232-9. Abstract
Tarantino P, Curigliano G. Defining the immunogram of breast cancer: A focus on clinical trials. Expert Opin Biol Ther 2019;19(5):383-5. Abstract
Hope S Rugo, MD
Adams S et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Ann Oncol 2019;30(3):405-11. Abstract
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39(1):1-10. Abstract
Cortés J et al. KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Proc ESMO 2019;Abstract LBA21.
Denkert et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: Results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol 2016;29(10):1155-64. Abstract
Dirix LY et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat 2018;167(3):671-686. Abstract
Domchek SM et al. MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody) — Additional breast cancer cohorts. San Antonio Breast Cancer Symposium 2018;Abstract OT3-05-03.
Emens LA et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol 2019;5(1):74-82. Abstract
Loi S et al. Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 2019;37(7):559-69. Abstract
Loi S et al. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study. San Antonio Breast Cancer Symposium 2017;Abstract GS2-06.
Nanda R et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol 2016;34(21):2460-7. Abstract
Park S et al. Comparison of standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast cancer ≥1cm. Proc ESMO Asia 2019;30(9). Abstract 8P.
Rugo HS et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res 2018;24(12):2804-11. Abstract
Salgado R et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol 2015;26(2):259-71. Abstract
Schmid P et al. IMpassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO 2019;Abstract 1003.
Schmid P et al. Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Proc AACR 2019;Abstract CT049.
Voorwerk et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: The TONIC trial. Nat Med 2019;25(6):920-8. Abstract
Mark E Robson, MD
Diéras VC et al. Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Proc ESMO 2019;Abstract LBA9.
Hurvitz SA et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: Detailed safety analyses from the phase III EMBRACA trial. Oncologist 2019;[Epub ahead of print]. Abstract
Litton JK. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). ASCO 2018;Abstract 508.
Litton JK et al. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 2017;3:49. Abstract
Litton J et al. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. San Antonio Breast Cancer Symposium 2017;Abstract GS6-07.
Loibl S et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomized, phase 3 trial. Lancet Oncol 2018;19(4):497-509. Abstract
Mouw KW et al. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov 2017;7(7):675-93. Abstract
Robson M et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. San Antonio Breast Cancer Symposium 2019;Abstract PD4-03.
Robson ME et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019;30(4):558-66. Abstract
Rugo HS et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 2016;375(1):23-34. Abstract
Professor Sherene Loi, MBBS, PhD
Bardia A et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 2019;380(8):741-51. Abstract
Iwata H et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. ASCO 2018;Abstract 2501.
Tan AR et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: A multicenter, randomized, open-label, phase 2 trial. Lancet Oncol 2019;20(11):1587-1601. Abstract